PROM1 and colorectal carcinoma: Subsequently, we compared the binding of clone (i) 293C3, (ii) AC133, which is used in other CD133 targeting cancer therapeutics [20], and (iii) W6B3C1 using a panel of five different CRC cell lines that reportedly express CD133 [21,22,23].